Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study-Reference-Cited by-同舟云学术

Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study

Published:2015-11-25 Issue:2 Volume:103 Page:243-250
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Muroi Kazuo,Miyamura Koichi,Okada Masaya,Yamashita Takuya,Murata Makoto,Ishikawa Takayuki,Uike Naokuni,Hidaka Michihiro,Kobayashi Ryoji,Imamura Masahiro,Tanaka Junji,Ohashi Kazuteru,Taniguchi Shuichi,Ikeda Takashi,Eto Tetsuya,Mori Masaki,Yamaoka Mariko,Ozawa Keiya

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-015-1915-9.pdf

Reference33 articles.

1. Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med. 2013;2:25–32.

2. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119–26.

3. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, et al. Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30–45.

4. Daly A. Remestemcel-L, the first cellular therapy product for the treatment of graft-versus-host disease. Drugs Today (Barc). 2012;48:773–83.

5. Newell LF, Deans RJ, Maziarz RT. Adult adherent stromal cells in the management of graft-versus-host disease. Expert Opin Biol Ther. 2014;14:231–46.

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality and Safety Considerations for Therapeutic Products Based on Extracellular Vesicles;Pharmaceutical Research;2024-08

2. Microcarrier-based clinical-grade manufacturing of therapeutic Wharton's jelly mesenchymal stromal cells;Cytotherapy;2024-07

3. Therapeutic applications of mesenchymal/medicinal stem/signaling cells preconditioned with external factors: Are there more efficient approaches to utilize their regenerative potential?;Life Sciences;2024-06

4. International Society for Cell and Gene Therapy Clinical Translation Committee recommendations on mesenchymal stromal cells in graft-versus-host disease: easy manufacturing is faced with standardizing and commercialization challenges;Cytotherapy;2024-05

5. Mesenchymal Stem Cell Extracellular Vesicles as a New Treatment Paradigm in Solid Abdominal Organ Transplantation: A Case Series;Stem Cells and Development;2024-03-01